X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Wockhardt with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs ADCOCK INGRAM (S. Africa) - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 WOCKHARDT LTD.   ADCOCK INGRAM
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-17
ADCOCK INGRAM
Jun-14
WOCKHARDT LTD./
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs1,129403-   
Low Rs627291-   
Sales per share (Unadj.) Rs363.1119.9-  
Earnings per share (Unadj.) Rs-20.4-30.2-  
Cash flow per share (Unadj.) Rs-7.0-25.0-  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs301.894.1-  
Shares outstanding (eoy) m110.55168.78-   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x2.42.9 83.6%   
Avg P/E ratio x-42.9-11.5 374.0%  
P/CF ratio (eoy) x-125.9-13.9 908.5%  
Price / Book Value ratio x2.93.7 78.9%  
Dividend payout %-48.90-   
Avg Mkt Cap Rs m97,06358,557 165.8%   
No. of employees `0006.84.3 157.7%   
Total wages/salary Rs m9,6653,675 263.0%   
Avg. sales/employee Rs Th5,931.84,714.3 125.8%   
Avg. wages/employee Rs Th1,428.1856.1 166.8%   
Avg. net profit/employee Rs Th-334.0-1,187.9 28.1%   
INCOME DATA
Net Sales Rs m40,14620,238 198.4%  
Other income Rs m1,143142 806.1%   
Total revenues Rs m41,28920,380 202.6%   
Gross profit Rs m128-3,507 -3.6%  
Depreciation Rs m1,489873 170.5%   
Interest Rs m2,253548 410.9%   
Profit before tax Rs m-2,472-4,787 51.6%   
Minority Interest Rs m0-13 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-211299 -70.6%   
Profit after tax Rs m-2,260-5,100 44.3%  
Gross profit margin %0.3-17.3 -1.8%  
Effective tax rate %8.5-6.2 -136.7%   
Net profit margin %-5.6-25.2 22.3%  
BALANCE SHEET DATA
Current assets Rs m46,16014,823 311.4%   
Current liabilities Rs m19,2588,340 230.9%   
Net working cap to sales %67.032.0 209.2%  
Current ratio x2.41.8 134.9%  
Inventory Days Days101111 90.8%  
Debtors Days Days94124 75.9%  
Net fixed assets Rs m40,1658,640 464.9%   
Share capital Rs m55394 588.2%   
"Free" reserves Rs m32,8140-   
Net worth Rs m33,36715,885 210.1%   
Long term debt Rs m31,9035,582 571.5%   
Total assets Rs m89,68730,008 298.9%  
Interest coverage x-0.1-7.7 1.3%   
Debt to equity ratio x1.00.4 272.1%  
Sales to assets ratio x0.40.7 66.4%   
Return on assets %0-15.2 0.1%  
Return on equity %-6.8-32.1 21.1%  
Return on capital %-0.3-19.8 1.7%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m6,9880-   
CASH FLOW
From Operations Rs m-2,6951,727 -156.0%  
From Investments Rs m-6,863-530 1,293.8%  
From Financial Activity Rs m12,5455,066 247.6%  
Net Cashflow Rs m3,0106,263 48.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.56 Rs / ZAR

Compare WOCKHARDT LTD. With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare WOCKHARDT LTD. With: AJANTA PHARMA  STERLING BIOTECH  NOVARTIS  TTK HEALTHCARE  AUROBINDO PHARMA  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Feb 23, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. - DISHMAN PHARMA COMPARISON

COMPARE WOCKHARDT LTD. WITH

MARKET STATS